Physician profile
Una Kosarac
NPI 1164984290
$3,326.81
in general payments reported to CMS, 2019-2025
20 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.24 · 2022: $79.38 · 2023: $1,019 · 2024: $1,192 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,235.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $701.71 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $569.17 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $519.26 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $488.53 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $306.40 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $202.48 | 2023-2025 | Freestyle Libre 3 |
| Amgen INC. | $112.67 | 2023-2025 | Repatha, Otezla, Repatha |
| Inspire Medical Systems, INC. | $99.76 | 2023-2025 | Inspire |
| Pfizer INC. | $55.39 | 2023-2024 | |
| Dynavax Technologies Corporation | $34.73 | 2023-2024 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $33.58 | 2022 | |
| Sanofi Pasteur INC. | $31.18 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.02 | 2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $28.00 | 2023 | Rexulti |
| Dexcom, INC. | $25.25 | 2024 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $21.89 | 2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $21.01 | 2023 | Nuvent |
| Astellas Pharma US INC | $19.02 | 2024 | Veozah |
| Currax Pharmaceuticals LLC | $13.52 | 2025 | Contrave |
| Merck Sharp & Dohme LLC | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Una Kosarac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.